Figures computed from official regulatory filings — .
Analysttarget 4.25 USD (+2261%) · consensus 4.5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 0.51% · institutions 2.88% · short 7.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for AEROSONIC CORP /DE/ only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
120 buys32 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| CHEMEROW DAVIDtrack record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Equels Thomas K.track record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Equels Thomas K.track record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CHEMEROW DAVIDtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Equels Thomas K.track record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CHEMEROW DAVIDtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Equels Thomas K.track record | OtherD (derivative) | $625K | Unusual size | SEC |
| CHEMEROW DAVIDtrack record | OtherD (derivative) | $625K | SEC |
| CHEMEROW DAVIDtrack record | Award | $3.4K | Unusual size | SEC |
| Equels Thomas K.track record | Buy | $823.9 | conv 49Cluster | SEC |
| Equels Thomas K.track record | Buy | $896.1 | conv 50Cluster | SEC |
| MITCHELL WILLIAM Mtrack record | Buy | $5.9K | conv 62ClusterFirst in 12mo | SEC |
| Equels Thomas K.track record | Buy | $59.1K | conv 89ClusterUnusual size | SEC |
| KELLNER TED D | Buy | $59.1K | conv 91ClusterFirst in 12mo | SEC |
| Equels Thomas K.track record | Buy | $2.5K | conv 41 | SEC |
| Rodino Peter W. IIItrack record | Buy | $45 | conv 42 | SEC |
| MITCHELL WILLIAM Mtrack record | Award | $5.4K | SEC |
| CHEMEROW DAVIDtrack record | Award | $5.4K | Unusual size | SEC |
| BRYAN NANCY | Award | $5.4K | SEC |
| Equels Thomas K.track record | Buy | $6.5K | conv 40 | SEC |
| Equels Thomas K.track record | Buy | $5.3K | conv 43 | SEC |
| CHEMEROW DAVIDtrack record | Award | $2.7K | SEC |
| BRYAN NANCY | Award | $5.4K | SEC |
| MITCHELL WILLIAM Mtrack record | Award | $5.4K | SEC |
| Equels Thomas K.track record | Buy | $10K | conv 44 | SEC |